From targeted therapy in ovarian cancer to personalizing therapy for ovarian cancer

Bibliography

• Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351(24):2519-29
   PubMed Web of Science ®Google Scholar
• Katsumata N, Yasuda M, Takahashi F, Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374:1331-38
   PubMed Web of Science ®Google Scholar
• Kauf ND. Is it time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer? J Clin Oncol 2008;26(1):9-10
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA, Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Eng J Med 2009;361:123-34
   PubMed Web of Science ®Google Scholar
• Fong PC, Yap TA, Boss DS, Poly (ADP) ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum free interval. J Clin Oncol 2010;28:2512-19
   PubMed Web of Science ®Google Scholar
• Audeh MW, Carmichael J, Penson RT, Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA 1 or BRCA 2 mutations and recurrent ovarian cancer: a proof of concept trial. Lancet 2010;376:245-51
   PubMed Web of Science ®Google Scholar
• Pal T, Permuth-Wey J, Betts JA, BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005;104:2807-16
   PubMed Web of Science ®Google Scholar
• Geisler JP, Hatterman-Zogg MA, Rathe JA, Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 2002;94:61-7
   Google Scholar
• Mukhopadhyay A, Elattar A, Cerbinstkaite A, Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to PARP inhibitors. Clin Cancer Res 2010;16:2344-51
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Spentzos D, Karlan BY, Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010;28:3555-61
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Hierte HW, Robidoux A, Can we define tumours that will respond to PARP inhibition? A phase II correlative study of olaparib in advanced seous ovarian cancer and triple-negative breast cancer. J Clin Oncol 2010;28:15S
   PubMed Web of Science ®Google Scholar
• Gomez-Raposo C, Mendiola M, Barriuso J, Angiogenesis and ovarian cancer. Clin Trans Oncol 2009;11:564-71
   PubMed Web of Science ®Google Scholar
• Burger RA, Sill MW, Monk BJ, Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:5165-71
   PubMed Web of Science ®Google Scholar
• Cannistra SA, Matulonis UA, Penson RT, Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5180-6
   PubMed Web of Science ®Google Scholar
• Burger RA, Brady MF, Bookman MA, Phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer: A Gynecologic Oncology Group study. J Clin Oncol 2010;28(Suppl 18): abstract LBA1
   Web of Science ®Google Scholar
• Perren T, Swart AM, Pfisterer J, ICON7: a phase III randomised Gynaecologic Cancer Intergroup trial of concurrent Bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer. Ann Oncol 2010;21(Suppl 8):LBA4
   Google Scholar
• Zweifel M, Jayson GC, Reed NS, Phase II trial of combrestatin A4 phosphate, carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol 2011; Epub ahead of print
   Google Scholar
• Karlan BY, Oza AM, Hansen VL, Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian carcinoma. J Clin Oncol 2010;28(Suppl 12 ): abstract 500
   PubMedGoogle Scholar
• Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet 2010;11:1172-83
   PubMed Web of Science ®Google Scholar
• Steffensen KD, Waldstrom M, Brandslund I, The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol 2010;117:109-16
   PubMed Web of Science ®Google Scholar
• Barriuso J, Mendiola M, Redondo A, Angiogenesis-related gene profile to predict outcome to multimodal therapy in advanced ovarian carcinoma. J Clin Oncol 2010;28(Suppl 15): abstract 5078
   Google Scholar
• Gomez-Raposo C, Mendiola M, Barriuso J, Molecular characterization of ovarian cancer. Gynecol Oncol 2010;118:88-92
   PubMed Web of Science ®Google Scholar